Scholarlink

Purpose of Review <p>With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody–drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has drastically improved. The use of EGFR-targeted therapies has shifted to include not only advanced/ metastatic disease but also to early-stage non-small cell lung cancer.</p> Recent Findings <p>Novel therapy options have sought to address the need for effective agents against acquired resistance mechanisms in EGFR mutations. Further, the role of tyrosine kinase inhibitors against EGFR mutation in the perioperative setting has been most recently evaluated. With early outcomes, clinicians are met with the need to guide patients through various treatment regimens, and mature survival results are anticipated for several key trials. Of import, the growing focus on personalized treatment options based on outcomes, quality-of-life, toxicity, tolerability, and various disease-related factors warrants consideration.</p> Summary <p>This review comprehensively describes frontline and subsequent-line therapy options for patients with early stage, unresectable/ locally advanced, and advanced/ metastatic stages of EGFR-mutant non-small cell lung cancer, including unprecedented therapeutic agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Abhinav Vyas,
  • Won Jin Jeon,
  • Sanad Alhushki,
  • Eric Singhi,
  • Fawzi Abu Rous,
  • Rajat Thawani,
  • Aakash Desai

摘要

Purpose of Review

With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody–drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has drastically improved. The use of EGFR-targeted therapies has shifted to include not only advanced/ metastatic disease but also to early-stage non-small cell lung cancer.

Recent Findings

Novel therapy options have sought to address the need for effective agents against acquired resistance mechanisms in EGFR mutations. Further, the role of tyrosine kinase inhibitors against EGFR mutation in the perioperative setting has been most recently evaluated. With early outcomes, clinicians are met with the need to guide patients through various treatment regimens, and mature survival results are anticipated for several key trials. Of import, the growing focus on personalized treatment options based on outcomes, quality-of-life, toxicity, tolerability, and various disease-related factors warrants consideration.

Summary

This review comprehensively describes frontline and subsequent-line therapy options for patients with early stage, unresectable/ locally advanced, and advanced/ metastatic stages of EGFR-mutant non-small cell lung cancer, including unprecedented therapeutic agents.